Ionis Pharmaceuticals: Q4 Earnings Insights

 

Shares of Ionis Pharmaceuticals IONS remained unaffected after the company reported Q4 results.

Quarterly Results

Earnings per share fell 39.10% over the past year to $0.81, which beat the estimate of $0.28.

Revenue of $290,000,000 decreased by 41.30% from the same period last year, which beat the estimate of $274,480,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Feb 24, 2021

Time: 09:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/952/39530

Price Action

Company's 52-week high was at $64.37

52-week low: $39.32

Price action over last quarter: Up 15.05%

Company Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

IONS Logo
IONSIonis Pharmaceuticals Inc
$36.19-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
37.25
Growth
Not Available
Quality
Not Available
Value
37.11
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Comments
Loading...